How to check Corona Remedies IPO allotment on Bigshare Services as GMP stays strong

Corona Remedies will finalise the allotment of its Rs 655 crore IPO on Thursday after a strong subscription that saw interest across investor categories. The grey market premium (GMP) stands at 28%, indicating healthy expectations for listing day gains, though actual performance will depend on market sentiment when the stock lists on December 15.

The IPO, entirely an offer for sale, drew 144.54 times overall subscription. QIBs led with 294 times bidding, NIIs subscribed 220.18 times, and retail investors submitted bids 30.39 times their quota. The employee quota was subscribed to 15.56 times.

Given the healthy institutional demand, the stock is expected to list above the issue price of Rs 1,062, although the final premium will depend on broader market cues next week.

How to check Corona Remedies IPO allotment

Allotment status will be available on Bigshare Services, the registrar for the IPO.

1. Visit Bigshare Services Allotment page: https://ipo.bigshareonline.com/ipo_status.html.
   
2. Select Corona Remedies IPO.
   
3. Enter your PAN, application number, or DP/Client ID to check the allotment.

On NSE Website

1. Visit the NSE Allotment page: https://www.nseindia.com/invest/check-ipo-allotment.
   
2. Select Equity.
   
3. Choose Corona Remedies.
   
   
4. Enter your PAN or application number.

If allotted, shares will be credited to demat accounts on December 12. Refunds for non-allottees will also be initiated the same day.

IPO details

The IPO comprised 61.71 lakh shares, entirely through an offer for sale worth Rs 655.37 crore, with no fresh issue component. The price band was Rs 1,062 at the upper end. The company also offered an employee discount of Rs 54 per share. Ahead of the issue opening, Corona Remedies raised Rs 194.86 crore from anchor investors on December 5.

About Corona Remedies

Corona Remedies is a fast-growing pharmaceutical company with a diversified portfolio spanning women’s health, cardio-diabetes, pain management, urology and key multispecialty segments. As of June 2025, the company owned 71 brands, backed by a strong field force of 2,671 medical representatives across 22 states, giving it deep reach in the domestic market.

Its two manufacturing facilities in Gujarat have an annual capacity of 1,285 million formulation units, covering tablets, capsules, and other dosage forms. Strong compliance with good manufacturing practices and a large chronic-care franchise have supported its growth among the top 30 Indian pharma companies.

Financial performance

Corona Remedies has posted steady financial improvements over the past three years. Revenue rose 18% in FY25 to Rs 1,202.35 crore, while profit after tax surged 65% to Rs 149.43 crore. For the quarter ended June 2025, PAT stood at Rs 46.20 crore.

Listing outlook

With a 28% GMP, robust institutional demand, and strong fundamentals, the Corona Remedies listing is expected to be firm. The company’s chronic-care portfolio, strong distribution, and consistent financials have helped draw long-term investors.

Still, given the subscription intensity and ongoing interest in quality pharma names, investors will watch December 15 closely to see whether the listing sustains the optimism reflected in grey market trends.